O-014 Azacitidine versus best supportive care before non-myeloablative allogeneic stem cell transplantation for MDS: A study by the SFGM-TC

MLA

Pierre Fenaux, et al. “O-014 Azacitidine versus Best Supportive Care before Non-Myeloablative Allogeneic Stem Cell Transplantation for MDS: A Study by the SFGM-TC.” Leukemia Research, vol. 37, May 2013, pp. S14–15. EBSCOhost, https://doi.org/10.1016/s0145-2126(13)70036-5.

APA

Pierre Fenaux, Noel Milpied, Natacha Maillard, A. Duhame, Jérôme Cornillon, Sylvie François, Yves Beguin, Mauricette Michallet, Patrice Chevallier, Nathalie Fegueux, Ibrahim Yakoub-Agha, Bruno Lioure, Son Nguyen, Didier Blaise, Claude-Eric Bulabois, M. Robin, G. Damaj, Marie T Rubio, Mohamad Mohty, & Anne Huyn. (2013). O-014 Azacitidine versus best supportive care before non-myeloablative allogeneic stem cell transplantation for MDS: A study by the SFGM-TC. Leukemia Research, 37, S14–S15. https://doi.org/10.1016/s0145-2126(13)70036-5

Chicago

Pierre Fenaux, Noel Milpied, Natacha Maillard, A. Duhame, Jérôme Cornillon, Sylvie François, Yves Beguin, et al. 2013. “O-014 Azacitidine versus Best Supportive Care before Non-Myeloablative Allogeneic Stem Cell Transplantation for MDS: A Study by the SFGM-TC.” Leukemia Research 37 (May): S14–15. doi:10.1016/s0145-2126(13)70036-5.